Tag: AKT inhibitor
Published on Apr 12
0 Comments
Capivasertib, a pioneering AKT inhibitor from AstraZeneca and Astex Pharmaceuticals, has received UK approval for HR+/HER2- breast cancer with specific genetic alterations. This marks a significant advancement following its recent FDA approval. Demonstrating a substantial reduction in disease progression, Capivasertib is poised to redefine options for patients, highlighting renewed focus on AKT inhibitors in cancer therapy.